Price$34.82+0.73 (+2.14%)
01:45 PM07:45 PM
News · 26 weeks58-86%
2026-02-012026-07-26
Mix2790d
- Other8(30%)
- Insider8(30%)
- SEC Filings8(30%)
- Offering2(7%)
- Analyst1(4%)
Latest news
25 items- INSIDERPresident and CFO Cvijic Christine Mikail sold $173,375 worth of shares (4,800 units at $36.12) as part of a pre-agreed trading plan (SEC Form 4)4 - Neurogene Inc. (0001404644) (Issuer)
- PRNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 96,450 shares of the Company’s common stock to six new employees (the "Inducement Grants") on July 6, 2026 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company’s 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listi
- INSIDERPresident and CFO Cvijic Christine Mikail sold $166,586 worth of shares (4,800 units at $34.71) as part of a pre-agreed trading plan (SEC Form 4)4 - Neurogene Inc. (0001404644) (Issuer)
- SECNeurogene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Neurogene Inc. (0001404644) (Filer)
- SECSEC Form 424B5 filed by Neurogene Inc.424B5 - Neurogene Inc. (0001404644) (Filer)
- PRNeurogene Inc. Announces Pricing of $125 Million Public OfferingNeurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the pricing of its previously announced public offering of 3,500,000 shares of its common stock at a public offering price per share of $30.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 666,666 shares of its common stock at a public offering price of $29.999999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.000001 per share and are exercisable immediately. The aggregate gross proceeds to Neurogene from the offering are expected to be
- SECSEC Form 424B5 filed by Neurogene Inc.424B5 - Neurogene Inc. (0001404644) (Filer)
- PRNeurogene Inc. Announces Proposed Public OfferingNeurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Neurogene expects to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or wh
- SECNeurogene Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Neurogene Inc. (0001404644) (Filer)
- PRNeurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome47 total developmental milestones gained across 10 participants, with durable treatment effect and no plateau or milestone loss through 30 months of follow-up 100% of participants improved in CGI-I score and gained ≥1 developmental milestone, with an average of 4.7 milestones per participant, and all gaining ≥1 developmental milestone in the past 12 months Developmental milestones were gained in a progressive, stepwise sequence, suggesting a restart of development post-treatment NGN-401 at the 1E15 vg dose remains generally well-tolerated (N=35) as of data cutoff date of June 16, 2026 Dosing complete in the EmboldenTM registrational trial with no treatment-related SAEs or DLTs as of
- INSIDERAmendment: SEC Form 4 filed by Director Woods Keith4/A - Neurogene Inc. (0001404644) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Woods Keith4/A - Neurogene Inc. (0001404644) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Woods Keith4/A - Neurogene Inc. (0001404644) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Woods Keith3/A - Neurogene Inc. (0001404644) (Issuer)
- SECNeurogene Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Neurogene Inc. (0001404644) (Filer)
- PRNeurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett SyndromeExceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to strong demand from Rett syndrome community NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026 Topline data from Embolden anticipated in 2H 2027 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the successful completion of dosing in the Embolden™ registrational trial of NGN-401, an investigational gene therapy designed to be a potential best-in-class, one-time treatment fo
- SECNeurogene Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Neurogene Inc. (0001404644) (Filer)
- ANALYSTRodman & Renshaw initiated coverage on Neurogene with a new price targetRodman & Renshaw initiated coverage of Neurogene with a rating of Buy and set a new price target of $70.00
- PRNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 17,045 shares of the Company's common stock to two new employees (the "Inducement Grants") on June 1, 2026 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listi
- SECNeurogene Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Neurogene Inc. (0001404644) (Filer)
- SECSEC Form 10-Q filed by Neurogene Inc.10-Q - Neurogene Inc. (0001404644) (Filer)
- PRNeurogene Reports First Quarter 2026 Financial Results and Highlights Recent UpdatesDosed ~90% of participants in Embolden™ registrational trial of NGN-401 for Rett syndrome; on track to complete dosing in the second quarter of 2026 NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026 Presentation at ASGCT Meeting highlighted therapeutic rationale for ICV delivery in CNS-targeted gene therapy, including NGN-401 Strong cash position provides runway through first quarter of 2028 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2026 finan
- PRNeurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene TherapyICV is a commonly used neurosurgical procedure performed across multiple therapeutic settings, including gene therapy Presentation adds to body of evidence that ICV administration results in broad biodistribution of gene therapy to the brain and nervous system Use of ICV administration in NGN-401 gene therapy program for Rett syndrome provides potential rationale for the multidomain and durable improvements observed in Phase 1/2 trial Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, highlighted data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meet
- INSIDERPresident and CFO Cvijic Christine Mikail sold $300,043 worth of shares (9,600 units at $31.25) as part of a pre-agreed trading plan (SEC Form 4)4 - Neurogene Inc. (0001404644) (Issuer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Shafer Christina4 - Neurogene Inc. (0001404644) (Issuer)
NGNE FAQ
6 questionsWhere does NGNE stock trade?
Neurogene Inc. (NGNE) is listed on NASDAQ.What sector and industry is NGNE in?
Neurogene Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Neurogene Inc. go public?
Neurogene Inc. (NGNE) completed its IPO in 2014.What are analysts saying about NGNE?
Neurogene Inc. has had 7 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy on 2026-06-03. Recent price targets range from $2400.00 to $4600.00.What companies are similar to NGNE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NGNE side-by-side with any of them on Quantisnow.How can I track NGNE on Quantisnow?
Quantisnow aggregates Neurogene Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NGNE to receive live email and push alerts on every new disclosure.